Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Vinorelbine

Tubulin Modulators

Antimitotic Agents

Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer

Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer

1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer
2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer

Cipterbin Combined With Vinorelbine

Xiaojia Wang, PHD

Jian Huang, chief doctor

Xiaojia Wang

To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer

A multi-center, randomized, open-label study on pharmacokinetics, safety, efficacy, and immunogenicity of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer. The main purpose was to compare pharmacokinetics Index between two groups, secondly to observe safety, efficacy, and immunogenicity

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

A Multi-center, Randomized, Open-label Study on Pharmacokinetics, Safety, Efficacy, and Immunogenicity of Cipterbin Combined With Vinorelbine Injection Every Week or Every Three Weeks in the Treatment of Patients With HER2-positive Metastatic Breast Cancer

The data will be shared from the trial begin for 10 years

Cmax after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.

Cmin after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.

AUC0-t after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.

AUCtau after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.

Tmax after the first administration and the third administration in the three-week administration group and the seventh administration in the one-week administration group.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC	NCT05131841	Metastatic Brea...	Cipterbin Combi...	18 Years - 70 Years	Zhejiang Cancer Hospital
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC	NCT05131841	Metastatic Brea...	Cipterbin Combi...	18 Years - 70 Years	Zhejiang Cancer Hospital

Spots Global Cancer Trial Database for cipterbin combined with vinorelbine